Nuclera, the biotechnology company accelerating protein expression and optimsation through its benchtop eProtein Discovery system, has announced that it has appointed Seth Benson as Chief Financial Officer. Seth joins CEO, Dr Michael Chen, on the executive team to advance commercial and strategic initiatives, drive revenue and support expansion of the business following the close of the Company’s USD $75 million financing round. Bringing extensive financial expertise in building operational and financial infrastructure, Seth will be instrumental in guiding Nuclera’s next phase of commercial expansion across key global markets.
With more than 20 years of leadership experience in finance, strategy and operations in the life sciences and healthcare sectors, Seth has a proven track record of scaling businesses, driving strategic growth, optimising operations and leading strategic financial initiatives. He has successfully led fundraising efforts, acquisitions, restructurings and IPOs including at Akoya Biosciences where he helped grow the company to more than 300 people and played a pivotal role in its IPO.
Seth joins Nuclera from Vizgen, a company improving human health through spatial genomics, where he led the finance, operations and IT functions as CFO and guided the organisation through its acquisition of Ultivue, a spatial proteomics company. Previously, as SVP Finance and Operations at Invaio Sciences, Seth managed a multi-national finance team during early product commercialisation and fundraising. He has additionally held investment banking positions at Morgan Stanley and Bank of America Merril Lynch.
Seth Benson, CFO, Nuclera, said: “I am delighted to join Nuclera, especially at such an exciting time for the company. Nuclera’s eProtein Discovery system addresses a critical bottleneck in protein production workflows, with the potential to significantly impact drug discovery. I look forward to working with Michael and the team to build on the Company’s strong foundation and drive commercial growth.”